Skip to main content
Top
Published in: Rheumatology International 4/2011

01-04-2011 | Case Report

Pseudo-pseudo Meigs syndrome developed under the leflunomide therapy

Authors: Cemal Bes, Mehmet Soy

Published in: Rheumatology International | Issue 4/2011

Login to get access

Abstract

Pseudo-pseudo Meigs syndrome or Tjalma syndrome is characterized by increased CA-125 level, pleural effusion and ascites in systemic lupus erythematosus (SLE) patients without over tumor. The disorder is relatively rare and it has been reported usually in SLE patients with impaired renal functions. Herein, we present a case of a 47-year-old female patient who developed Tjalma syndrome after administration of leflunomide for rheumatoid arthritis. Surprisingly renal functions of our patient were found in normal limits. This is the first case of Tjalma syndrome that is developed in normal renal functions and the probable role of leflunomide therapy is discussed.
Literature
1.
go back to reference Meigs JV (1954) Pelvic tumors other than fibromas of the ovary with ascites and hydrothorax. Obstet Gynecol 3:471–486PubMed Meigs JV (1954) Pelvic tumors other than fibromas of the ovary with ascites and hydrothorax. Obstet Gynecol 3:471–486PubMed
2.
go back to reference Widra EA, Armstrong J (1995) Pseudo-Meigs’ syndrome and lupus. Int J Gynaecol Obstet 49(2):193–194PubMedCrossRef Widra EA, Armstrong J (1995) Pseudo-Meigs’ syndrome and lupus. Int J Gynaecol Obstet 49(2):193–194PubMedCrossRef
3.
go back to reference Tjalma WA (2005) Ascites, pleural effusion, and CA 125 elevation in an SLE patient, either a Tjalma syndrome or, due to the migrated Filshie clips, a pseudo-Meigs syndrome. Gynecol Oncol 97(1):288–291PubMedCrossRef Tjalma WA (2005) Ascites, pleural effusion, and CA 125 elevation in an SLE patient, either a Tjalma syndrome or, due to the migrated Filshie clips, a pseudo-Meigs syndrome. Gynecol Oncol 97(1):288–291PubMedCrossRef
5.
go back to reference Schmitt R, Weichert W, Schneider W, Luft FC, Kettritz R (2005) Pseudo-pseudo Meigs’ syndrome. Lancet 366(9497):1672PubMedCrossRef Schmitt R, Weichert W, Schneider W, Luft FC, Kettritz R (2005) Pseudo-pseudo Meigs’ syndrome. Lancet 366(9497):1672PubMedCrossRef
6.
go back to reference Ural UM, Kiliç A, Güngör T, Özdal B, Mollamahmutoglu L (2008) Tjalma’s or pseudo-pseudo-Meigs’ syndrome: a case report. Clin Exp Dermatol 33(3):363–364PubMedCrossRef Ural UM, Kiliç A, Güngör T, Özdal B, Mollamahmutoglu L (2008) Tjalma’s or pseudo-pseudo-Meigs’ syndrome: a case report. Clin Exp Dermatol 33(3):363–364PubMedCrossRef
7.
go back to reference Patsner B (2000) Meigs syndrome and bfalse positiveQ preoperative serum CA-125 levels: analysis of ten cases. Eur J Gynaecol Oncol 21:362–363PubMed Patsner B (2000) Meigs syndrome and bfalse positiveQ preoperative serum CA-125 levels: analysis of ten cases. Eur J Gynaecol Oncol 21:362–363PubMed
8.
go back to reference Abramov Y, Anteby SO, Fasouliotis SJ, Barak V (2002) The role of inflammatory cytokines in Meigs’ syndrome. Obstet Gynecol 99:917–919PubMedCrossRef Abramov Y, Anteby SO, Fasouliotis SJ, Barak V (2002) The role of inflammatory cytokines in Meigs’ syndrome. Obstet Gynecol 99:917–919PubMedCrossRef
9.
go back to reference Robak E, Wozniacka A, Sysa-Jedrejowska A, Stepien H, Robak T (2002) Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus 11(6):348–355PubMedCrossRef Robak E, Wozniacka A, Sysa-Jedrejowska A, Stepien H, Robak T (2002) Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus 11(6):348–355PubMedCrossRef
10.
go back to reference Fox RI (1998) Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl 53:20–26PubMed Fox RI (1998) Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl 53:20–26PubMed
11.
go back to reference Remer CF, Weisman MH, Wallace DJ (2001) Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10:480–483PubMedCrossRef Remer CF, Weisman MH, Wallace DJ (2001) Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10:480–483PubMedCrossRef
12.
go back to reference Tam LS, Li EK, Wong CK, Lam CW, Li WC, Szeto CC (2006) Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis 65(3):417–418PubMedCrossRef Tam LS, Li EK, Wong CK, Lam CW, Li WC, Szeto CC (2006) Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis 65(3):417–418PubMedCrossRef
13.
go back to reference Kremer JM, Cannon GW (2004) Benefit/risk of leflunomide in rheumatoid arthritis. Clin Exp Rheumatol 22(5 Suppl 35):S95–S100 Kremer JM, Cannon GW (2004) Benefit/risk of leflunomide in rheumatoid arthritis. Clin Exp Rheumatol 22(5 Suppl 35):S95–S100
14.
go back to reference Gensburger D, Kawashima M, Marotte H, Kanitakis J, Miossec P (2005) Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis 64(1):153–155PubMedCrossRef Gensburger D, Kawashima M, Marotte H, Kanitakis J, Miossec P (2005) Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis 64(1):153–155PubMedCrossRef
15.
go back to reference Grabar PB, Rozman B, Logar D, Praprotnik S, Dolzan V (2009) Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann Rheum Dis 68(8):1367–1368PubMedCrossRef Grabar PB, Rozman B, Logar D, Praprotnik S, Dolzan V (2009) Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann Rheum Dis 68(8):1367–1368PubMedCrossRef
Metadata
Title
Pseudo-pseudo Meigs syndrome developed under the leflunomide therapy
Authors
Cemal Bes
Mehmet Soy
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1190-2

Other articles of this Issue 4/2011

Rheumatology International 4/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine